NCT03400332 2026-02-24
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
17 trialsNCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT03739710 2025-06-15
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Completed
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT02904226 2023-07-03
ICONIC
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT03251924 2023-02-28
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT01804465 2021-08-18
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT03026166 2020-07-17
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
AbbVie
Phase 1/2 Terminated
NCT02221739 2020-05-11
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NYU Langone Health
Phase 1/2 Completed
NCT00323882 2014-08-28
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed